#Drug Development

Biotech's AI Infusion: A Tremendous Opportunity

NRG Therapeutics Secures £50M Series B for ALS, Parkinson's Drugs

NRG Therapeutics secured £50 million in Series B funding, led by SV Health Investors’ Dementia Discovery Fund. This investment will advance mitochondrial-targeting treatments for neurodegenerative diseases. The company aims to transition its pipeline, including lead candidate NRG5051 for ALS and Parkinson's, into...

ArcaScience Secures $7M for AI Drug Development Platform Expansion

The platform transforms biomedical data into actionable benefit-risk insights for drug development.

Mabylon Raises €31.8M to Advance Allergy Antibody Pipeline

Mabylon, a Swiss biotech, secured €31.8 million in new funding. This investment will advance its lead peanut allergy program and early-stage pipeline. The funding came from existing private investors, including former Roche management and board members.

ASTRA Therapeutics Raises €8.3M for Precision Animal Parasiticides

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

Upstream Bio IPOs at $830M Valuation, Raises $255M, Advances Respiratory Treatments